This content is from: Premium
Hedge Fund Titans Bet Big on Drugmaker Shire’s Success
John Paulson, Dan Loeb, and other prominent Investors move into an industry in flux.
Illustration by Renaud Vigor.For the past few years, Shire has been defined by two things: popular niche drugs and failed M&A. That changed in June of this year, when the Irish-based drugmaker pulled off the biggest acquisition in its history by buying Illinois-based biopharmaceuticals company Baxalta. Purchasing the $6 billion
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.